Soleno Therapeutics (SLNO) Non Operating Income (2017 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Non Operating Income of $3.6 million for Q1 2026, up 84.52% year-over-year from $2.0 million in Q1 2025, and down 3.86% quarter-over-quarter from $3.8 million in Q4 2025.
Soleno Therapeutics (SLNO) Non Operating Income (2017 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Non Operating Income for 10 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 84.52% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $13.1 million (up 12.18% YoY), while the FY2025 annual figure was $11.5 million, down 2.92% from the prior year.
- Non Operating Income declined to $3.6 million in Q1 2026 per SLNO's latest filing, from $3.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.9 million in Q3 2025 and bottomed at -$479000.0 in Q3 2023.
- Historically, Non Operating Income has averaged $1.7 million across 5 years, with a median of $2.0 million in 2025.
- On a YoY basis, Non Operating Income climbed as much as 2008.06% in 2023 and fell as far as 565.05% in 2023.
- Soleno Therapeutics' Non Operating Income stood at $124000.0 in 2022, then surged by 2008.06% to $2.6 million in 2023, then gained by 19.89% to $3.1 million in 2024, then rose by 20.64% to $3.8 million in 2025, then declined by 3.86% to $3.6 million in 2026.
- Business Quant data shows SLNO's Non Operating Income at $3.6 million in Q1 2026, $3.8 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 3.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.64 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Sep 30, 2025 | 3.91 Mn |
| Jun 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 3.01 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | -479,000.00 |
| Jun 30, 2023 | 148,000.00 |
| Mar 31, 2023 | 113,000.00 |
| Dec 31, 2022 | 124,000.00 |
| Sep 30, 2022 | 103,000.00 |
| Jun 30, 2022 | 54,000.00 |
| Mar 31, 2022 | 49,000.00 |
| Dec 31, 2021 | 173,000.00 |
| Sep 30, 2021 | 146,000.00 |
| Jun 30, 2021 | 97,000.00 |